Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon

VIVA.14: Zilver PTX holds strong at five years

At five years, the Zilver PTX stent proved to be a durable treatment for peripheral artery disease with sustained benefit, results presented Nov. 4 at the 2014 Vascular Interventional Advances (VIVA) meeting showed.

Thumbnail

Culprit-vessel PCI in STEMI improves outcomes through 1 year

For multivessel disease, “if it isn’t broken, don’t fix it” may also apply to PCI. A retrospective look at a London cohort points to treating only the culprit vessel of STEMI as the best method for improved patient outcomes through one year.

Treatment periods, fatality rates illuminate DAPT choices

A comparison of randomized clinical trials that assessed dual-antiplatelet therapy (DAPT) durations showed such trials should include treatment periods and case fatality rates to better understand the risks and benefits. Using this approach, researchers saw hints of a mortality advantage with 12-month DAPT.

Thumbnail

Patients with nonobstructive CAD still at risk for MI, death

Coronary artery disease (CAD) may not have to be obstructive to increase patients’ risks for MI or all-cause mortality. According to a study published online Nov. 4 in JAMA, patients diagnosed with nonobstructive CAD through coronary angiography were two times more likely to experience MI within one year of diagnosis as those with no apparent CAD. 

Two 2nd-gen drug-eluting stents equally safe, effective at 3 years

Three-year outcomes post-stenting reveal favorable and similar results for patients with and without bifurcated lesions treated with second-generation drug-eluting stents. 

Medtronic launches Resolute Onyx Drug-Eluting Stent following CE mark

Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européene) mark and international launch of the Resolute Onyx Drug-Eluting Stent (DES). The first live patient implant of the Resolute Onyx DES occurred recently during the XII International Course of Endovascular and Myocardial Therapy in Madrid, Spain. The Resolute Onyx Drug-Eluting Stent is not approved in the United States.

Minister for Health launches statewide registry for Victoria’s cardiac patients

Victorian Hospitals will be better equipped to measure the quality of care for their cardiac patients, under a new project that collects and compares data on coronary angioplasty practice.

Thumbnail

Shunning FFR, most physicians choose to eyeball angiography results

Most cardiologists who participated in an international web survey used angiography results to assess intermediate stenoses over requesting fractional flow reserve (FFR) measurements or other techniques, contrary to guidelines. This was the case even when resources were not an obstacle.

Displaying 1625 - 1632 of 2708

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.